Market Cap 551.06B
Revenue (ttm) 94.19B
Net Income (ttm) 26.80B
EPS (ttm) N/A
PE Ratio 21.13
Forward PE 19.59
Profit Margin 28.46%
Debt to Equity Ratio 0.46
Volume 6,310,518
Avg Vol 7,759,444
Day's Range N/A - N/A
Shares Out 2.41B
Stochastic %K 82%
Beta 0.27
Analysts Strong Sell
Price Target $260.46

Company Profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospit...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 732 524 0400
Website: www.jnj.com
Address:
One Johnson & Johnson Plaza, New Brunswick, United States
BillionerOfKing
BillionerOfKing May. 20 at 4:58 PM
$JNJ Current Stock Price: $229.72 Contracts to trade: $230.0 JNJ May 22 2026 Call Entry: $1.51 Exit: $2.36 ROI: 56% Hold ~28 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
JIMMYRIZZ
JIMMYRIZZ May. 20 at 3:35 PM
$DVLT 👏👏👏👏👏 Don’t sleep on these prices 🕵️‍♂️🫡👏🍀🍀🍀🍀🍀 DATAVAULT !!! $NVO $JNJ $INO $MRNA DatavaulT with Wellgistics Health to integrate its "EinsteinRx" AI platform into the pharmacy chain, creating a massive digital health footprint.
1 · Reply
capitalthinktank
capitalthinktank May. 20 at 2:41 PM
$IBRX — The FDA has accepted the sBLA to expand Anktiva into MNBIC papillary bladder cancer, with a PDUFA date of January 6, 2027, under standard review. The development is positive, but approval remains uncertain. The FDA reiterated concerns over single-arm trial data in papillary disease, which the company acknowledged. If approved on this basis, it could set a regulatory precedent for future filings. Competition in bladder cancer remains strong, with $JNJ also potentially advancing expanded approval for Inlexzo.
2 · Reply
FibonacciTrader_
FibonacciTrader_ May. 20 at 1:17 PM
$IBRX — FDA accepted the sBLA to expand Anktiva into MNBIC papillary, with a PDUFA date set for Jan 6, 2027 (standard review). On the surface, this is a constructive regulatory step for ImmunityBio, but the fine print matters here. FDA is still flagging concerns around reliance on single-arm trial data in papillary disease, which keeps approval uncertainty on the table. Even the company acknowledged those limitations. Bigger picture: if this ultimately gets approved on single-arm evidence, it could quietly reset expectations for how similar oncology drugs get evaluated going forward—opening the door for competitors like $JNJ to push their own expansion strategies faster with Inlexzo. Positive headline, but far from a clear approval path. Market will likely trade the nuance, not just the headline.
2 · Reply
cwEWF
cwEWF May. 20 at 9:36 AM
$JNJ expected correction to end into daily #bluebox between 227.8 - 215.82 before rally again It ended at 220.37 low in #Bluebox & favors rally above 259.3 or at least 3 swing bounce. Buyers looking for more upside to create risk free longs. #Elliottwave #JNJ
0 · Reply
parcha
parcha May. 20 at 12:44 AM
Final Trade: JNJ, SMH, APA $JNJ $SMH $APA https://www.cnbc.com/video/2026/05/19/final-trade-jnj-smh-apa.html?__source=iosappshare%7Ccom.stocktwits.StockTwits.STShareExtension
0 · Reply
Dovkav
Dovkav May. 19 at 11:51 PM
0 · Reply
ReaLiLJ
ReaLiLJ May. 19 at 6:01 PM
$CODX $GOVX $MRK $JNJ https://time.com/article/2026/05/19/trump-concerned-ebola-outbreak-american-tests-positive-cases-deaths-rise/ Only a matter of time before Washington releases something.
0 · Reply
trenddetector
trenddetector May. 19 at 4:48 PM
Tecvayli + Darzalex / Johnson & Johnson / $JNJ $JNJ Tecvayli (teclistamab) + Darzalex combo just got FDA approval for relapsed/refractory multiple myeloma. Dual pathway targeting — BCMA bispecific meets CD38 antibody. Full breakdown now live at YourCancerPath.com/multiple-myeloma #JNJ #Myeloma
0 · Reply
Diefreeandsell
Diefreeandsell May. 19 at 4:30 PM
$IBRX t+o settlements too, so no waiting for days to buy ibrx stock when you sell $JNJ, $MRK ! Mm’s paychecks will be shrinking SOON!
0 · Reply
Latest News on JNJ
CVS to drop J&J's Stelara from its main formularies

May 5, 2026, 9:15 AM EDT - 15 days ago

CVS to drop J&J's Stelara from its main formularies

CVS


J&J's $1.7 Billion Drug Ushers in Age of Psychedelic Medicine

May 2, 2026, 4:00 AM EDT - 18 days ago

J&J's $1.7 Billion Drug Ushers in Age of Psychedelic Medicine


Why These 3 Forever Stocks Belong on Your Watchlist

Apr 28, 2026, 11:10 AM EDT - 22 days ago

Why These 3 Forever Stocks Belong on Your Watchlist

WMT XOM


J&J sees AI halving the time to generate drug development leads

Apr 27, 2026, 11:03 AM EDT - 23 days ago

J&J sees AI halving the time to generate drug development leads


Johnson & Johnson Transcript: AGM 2026

Apr 23, 2026, 10:00 AM EDT - 27 days ago

Johnson & Johnson Transcript: AGM 2026


Johnson & Johnson CFO on the company's robotic surgical system

Apr 14, 2026, 10:51 AM EDT - 5 weeks ago

Johnson & Johnson CFO on the company's robotic surgical system


Johnson & Johnson Earnings Call Transcript: Q1 2026

Apr 14, 2026, 8:30 AM EDT - 5 weeks ago

Johnson & Johnson Earnings Call Transcript: Q1 2026


Johnson & Johnson Earnings release: Q1 2026

Apr 14, 2026, 8:30 AM EDT - 5 weeks ago

Johnson & Johnson Earnings release: Q1 2026


Johnson & Johnson Slides: Q1 2026

Apr 14, 2026, 8:30 AM EDT - 5 weeks ago

Johnson & Johnson Slides: Q1 2026


Johnson & Johnson Quarterly report: Q1 2026

Apr 14, 2026, 8:30 AM EDT - 5 weeks ago

Johnson & Johnson Quarterly report: Q1 2026


J&J raises guidance for 2026 on strong start to the year

Apr 14, 2026, 6:55 AM EDT - 5 weeks ago

J&J raises guidance for 2026 on strong start to the year


Johnson & Johnson reports Q1 2026 results, raises 2026 outlook

Apr 14, 2026, 6:20 AM EDT - 5 weeks ago

Johnson & Johnson reports Q1 2026 results, raises 2026 outlook


J&J's First-Quarter Sales Grow on Cancer-Drug Strength

Apr 14, 2026, 6:20 AM EDT - 5 weeks ago

J&J's First-Quarter Sales Grow on Cancer-Drug Strength


The Big 3: ORCL, JNJ, SBUX

Mar 19, 2026, 1:00 PM EDT - 2 months ago

The Big 3: ORCL, JNJ, SBUX

ORCL SBUX


US FDA approves J&J's oral psoriasis pill

Mar 18, 2026, 8:31 AM EDT - 2 months ago

US FDA approves J&J's oral psoriasis pill


BillionerOfKing
BillionerOfKing May. 20 at 4:58 PM
$JNJ Current Stock Price: $229.72 Contracts to trade: $230.0 JNJ May 22 2026 Call Entry: $1.51 Exit: $2.36 ROI: 56% Hold ~28 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
JIMMYRIZZ
JIMMYRIZZ May. 20 at 3:35 PM
$DVLT 👏👏👏👏👏 Don’t sleep on these prices 🕵️‍♂️🫡👏🍀🍀🍀🍀🍀 DATAVAULT !!! $NVO $JNJ $INO $MRNA DatavaulT with Wellgistics Health to integrate its "EinsteinRx" AI platform into the pharmacy chain, creating a massive digital health footprint.
1 · Reply
capitalthinktank
capitalthinktank May. 20 at 2:41 PM
$IBRX — The FDA has accepted the sBLA to expand Anktiva into MNBIC papillary bladder cancer, with a PDUFA date of January 6, 2027, under standard review. The development is positive, but approval remains uncertain. The FDA reiterated concerns over single-arm trial data in papillary disease, which the company acknowledged. If approved on this basis, it could set a regulatory precedent for future filings. Competition in bladder cancer remains strong, with $JNJ also potentially advancing expanded approval for Inlexzo.
2 · Reply
FibonacciTrader_
FibonacciTrader_ May. 20 at 1:17 PM
$IBRX — FDA accepted the sBLA to expand Anktiva into MNBIC papillary, with a PDUFA date set for Jan 6, 2027 (standard review). On the surface, this is a constructive regulatory step for ImmunityBio, but the fine print matters here. FDA is still flagging concerns around reliance on single-arm trial data in papillary disease, which keeps approval uncertainty on the table. Even the company acknowledged those limitations. Bigger picture: if this ultimately gets approved on single-arm evidence, it could quietly reset expectations for how similar oncology drugs get evaluated going forward—opening the door for competitors like $JNJ to push their own expansion strategies faster with Inlexzo. Positive headline, but far from a clear approval path. Market will likely trade the nuance, not just the headline.
2 · Reply
cwEWF
cwEWF May. 20 at 9:36 AM
$JNJ expected correction to end into daily #bluebox between 227.8 - 215.82 before rally again It ended at 220.37 low in #Bluebox & favors rally above 259.3 or at least 3 swing bounce. Buyers looking for more upside to create risk free longs. #Elliottwave #JNJ
0 · Reply
parcha
parcha May. 20 at 12:44 AM
Final Trade: JNJ, SMH, APA $JNJ $SMH $APA https://www.cnbc.com/video/2026/05/19/final-trade-jnj-smh-apa.html?__source=iosappshare%7Ccom.stocktwits.StockTwits.STShareExtension
0 · Reply
Dovkav
Dovkav May. 19 at 11:51 PM
0 · Reply
ReaLiLJ
ReaLiLJ May. 19 at 6:01 PM
$CODX $GOVX $MRK $JNJ https://time.com/article/2026/05/19/trump-concerned-ebola-outbreak-american-tests-positive-cases-deaths-rise/ Only a matter of time before Washington releases something.
0 · Reply
trenddetector
trenddetector May. 19 at 4:48 PM
Tecvayli + Darzalex / Johnson & Johnson / $JNJ $JNJ Tecvayli (teclistamab) + Darzalex combo just got FDA approval for relapsed/refractory multiple myeloma. Dual pathway targeting — BCMA bispecific meets CD38 antibody. Full breakdown now live at YourCancerPath.com/multiple-myeloma #JNJ #Myeloma
0 · Reply
Diefreeandsell
Diefreeandsell May. 19 at 4:30 PM
$IBRX t+o settlements too, so no waiting for days to buy ibrx stock when you sell $JNJ, $MRK ! Mm’s paychecks will be shrinking SOON!
0 · Reply
oceanviewhi
oceanviewhi May. 19 at 11:55 AM
$IBRX Clinical and Commercial Showdown: Why Anktiva + BCG "Blows Away" J&J’s TAR-200 the head-to-head data comparing ImmunityBio’s ($IBRX) Anktiva platform to Johnson & Johnson's ($JNJ) TAR-200 is the ultimate valuation driver. J&J has positioned TAR-200 (an intravesical drug-delivery system releasing gemcitabine) as the primary threat to Anktiva’s market share. However, the latest clinical comparative data released at AUA 2026 and summarized this morning proves that Anktiva's "living vaccine" approach completely outclasses J&J’s mechanical device on every major clinical metric. 1. Durability of Response (DOR): The Ultimate Clinical Decider The single most important metric in bladder cancer is how long a patient remains cancer-free. The Anktiva Standard: The QUILT-3.032 trial demonstrated a median Duration of Response (DOR) of 47.0 months in patients who achieved a Complete Response (CR). This is an unprecedented timeline that allows patients to keep their bladders for years.
0 · Reply
CFJHauser
CFJHauser May. 19 at 11:51 AM
0 · Reply
ReaLiLJ
ReaLiLJ May. 19 at 10:54 AM
$GOVX $SBFM $JNJ $MRK https://www.nbcnews.com/world/africa/ebola-outbreak-deaths-rise-scale-speed-concerns-who-congo-uganda-rcna345833 https://www.nytimes.com/2026/05/19/world/africa/ebola-outbreak-deaths-congo-who.html https://www.reuters.com/business/healthcare-pharmaceuticals/who-chief-concerned-speed-scale-ebola-outbreak-cases-rise-2026-05-19/
0 · Reply
ElliottwaveForecast
ElliottwaveForecast May. 19 at 9:35 AM
$JNJ favors rally from daily #Bluebox area targeting 259.3, while holds above 220.37 low It favors rally in (1) of ((5)) and expect continuation within January-2025 bull run explained in article https://elliottwave-forecast.com/stock-market/jnj-forecast-buyers-should-enter-227-8-215-8-area/ #Elliottwave #JNJ
0 · Reply
Ataifanboymentalhealthz
Ataifanboymentalhealthz May. 19 at 1:50 AM
$KAPA my guess $JNJ because ERLEADA (apalutamide) works but suffers resistance. Kairos is testing ENV105 with it and ZYTIGA. But could also be $PFE with XTANDI. Those would be my guesses
0 · Reply
ReaLiLJ
ReaLiLJ May. 18 at 7:55 PM
$GOVX https://www.bbc.com/news/articles/cq6pz60p996o $JNJ $MRK
0 · Reply
SuperGreenToday
SuperGreenToday May. 18 at 7:00 PM
$JNJ Share Price: $228.50 Contract Selected: Jun 12, 2026 $230 Calls Buy Zone: $3.53 – $4.36 Target Zone: $6.53 – $7.98 Potential Upside: 75% ROI Time to Expiration: 24 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
falcon_trader11
falcon_trader11 May. 18 at 6:15 PM
Not many small biotech names can reference relationships tied to $JNJ and $IDXX . $HYFT ecosystem keeps getting more interesting.
0 · Reply
trenddetector
trenddetector May. 18 at 3:13 PM
$JNJ Multiple myeloma is one of those diagnoses that can feel like the floor just dropped out. Patients prescribed Darzalex are often already deep into their treatment journey and looking for any edge they can find. YourCancerPath.com gives myeloma patients a free, anonymous place to understand their options — Darzalex included — without having to dig through dense medical journals or pay for a navigator. If you have a friend or family member fighting multiple myeloma, please pass this along. Sometimes just knowing there's a clear resource makes the next step feel possible. 🔗 YourCancerPath.com #multiplemyeloma #Darzalex #JNJ #YourCancerPath
0 · Reply
CapitalMonk
CapitalMonk May. 18 at 2:17 PM
$JNJ Price: $226.30 (-0.18%) Trend: Bullish Market Bias (7D): Sideways ⚖️ Expected Range: ±0.79% RSI: 47.4 | Momentum: Moderate Volume: -89.5% vs avg Volatility: 1.26% Support: $220.37 | Resistance: $232.14 Sourch: http://marketbaubles.com/
0 · Reply
Diefreeandsell
Diefreeandsell May. 18 at 1:25 PM
$IBRX $JNJ $MRK $XBI $IBB We already knew this, didn't we? The general consensus emerging from the comparison data is that if the BCG supply chain holds, Anktiva + BCG delivers superior multi-year durability and a less invasive administration cycle compared to the mechanical maintenance required by TAR-200, strongly positioning it to command the standard of care for long-term disease-free survival. SOC SOC!
0 · Reply
Diefreeandsell
Diefreeandsell May. 18 at 12:13 PM
$IBRX I assume this will be mentioned in40 mins during caparison data presentation: $JNJ TAR-200: The durability drops off a bit quicker over time compared to Anktiva, tracking closer to a $46% CR rate at 12 months and $42% at 24 months. It requires placing and later retrieving a physical drug-delivery system from the bladder via a cystoscopic office procedure every few weeks. Anktiva is a straightforward intravesical instillation (catheter fluid), but it must be administered alongside BCG. If a urologist has a stable supply of BCG, Anktiva + BCG is highly favored for long-term, multi-year disease-free survival and true bladder preservation. So they are solving the BCG shortage problem at least 2 ways and will become the SOC! Thanks for nothing $MRK !
1 · Reply